Cure My Disease

Don't miss your cure!

 Log in / Sign up

Immunotherapy blinatumomab shows promise in kids with relapsed leukemia

NCT ID NCT02393859

Completed Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial tested the drug blinatumomab in 111 children with high-risk relapsed B-precursor acute lymphoblastic leukemia (ALL). Blinatumomab is an immunotherapy that helps the body's immune cells attack cancer cells. The study compared blinatumomab to standard chemotherapy as consolidation therapy after initial treatment. The goal was to see if blinatumomab could improve event-free survival (time without cancer returning) and overall survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

blinatumomab (Blincyto)

What this could lead to

If successful, this could offer a more effective and less toxic treatment option for children with relapsed acute lymphoblastic leukemia.

What could go wrong

This is a completed Phase 3 trial, but results may not apply to all patients. Blinatumomab can cause serious side effects like cytokine release syndrome and neurological problems.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEUKEMIA, ACUTE LYMPHOBLASTIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

immunoproliferative disorder lymphoblastic leukemia, acute, with lymphomatous features lymphoproliferative syndrome neoplasm precursor B-cell acute lymphoblastic leukemia Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LEUKEMIA, ACUTE LYMPHOBLASTIC

Contacts and locations

Locations

  • Research Site

    Ciudad Autonoma de Buenos Aires, Buenos Aires, C1199ABB, Argentina

  • Research Site

    Randwick, New South Wales, 2031, Australia

  • Research Site

    Westmead, New South Wales, 2145, Australia

  • Research Site

    South Brisbane, Queensland, 4101, Australia

  • Research Site

    Parkville, Victoria, 3052, Australia

  • Research Site

    Graz, 8036, Austria

  • Research Site

    Innsbruck, 6020, Austria

  • Research Site

    Vienna, 1090, Austria

  • Research Site

    Brussels, 1020, Belgium

  • Research Site

    Brussels, 1200, Belgium

  • Research Site

    Ghent, 9000, Belgium

  • Research Site

    Leuven, 3000, Belgium

  • Research Site

    Liège, 4000, Belgium

  • Research Site

    Curitba, Paraná, 81520-060, Brazil

  • Research Site

    Porto Alegre, Rio Grande do Sul, 90035-903, Brazil

  • Research Site

    São Paulo, São Paulo, 04039-001, Brazil

  • Research Site

    São Paulo, São Paulo, 08270-070, Brazil

  • Research Site

    Prague, 150 06, Czechia

  • Research Site

    København Ø, 2100, Denmark

  • Research Site

    Bordeaux, 33076, France

  • Research Site

    Lille, 59037, France

  • Research Site

    Lyon, 69008, France

  • Research Site

    Marseille, 13385, France

  • Research Site

    Montpellier, 34295, France

  • Research Site

    Nantes, 44093, France

  • Research Site

    Paris, 75012, France

  • Research Site

    Paris, 75019, France

  • Research Site

    Strasbourg, 67200, France

  • Research Site

    Vandœuvre-lès-Nancy, 54511, France

  • Research Site

    Berlin, 13353, Germany

  • Research Site

    Düsseldorf, 40225, Germany

  • Research Site

    Erlangen, 91054, Germany

  • Research Site

    Essen, 45122, Germany

  • Research Site

    Frankfurt am Main, 60590, Germany

  • Research Site

    Freiburg im Breisgau, 79106, Germany

  • Research Site

    Giessen, 35392, Germany

  • Research Site

    Hamburg, 20246, Germany

  • Research Site

    Hanover, 30625, Germany

  • Research Site

    Jena, 07740, Germany

  • Research Site

    Kiel, 24105, Germany

  • Research Site

    München, 80337, Germany

  • Research Site

    Münster, 48149, Germany

  • Research Site

    Tübingen, 72076, Germany

  • Research Site

    Ulm, 89075, Germany

  • Research Site

    Würzburg, 97080, Germany

  • Research Site

    Goudi, 11527, Greece

  • Research Site

    Haifa, 3109601, Israel

  • Research Site

    Jerusalem, 9112001, Israel

  • Research Site

    Petah Tikva, 4920235, Israel

  • Research Site

    Tel Aviv, 6423906, Israel

  • Research Site

    Tel Litwinsky, 5262000, Israel

  • Research Site

    Bologna, 40138, Italy

  • Research Site

    Genova, 16147, Italy

  • Research Site

    Monza (MB), 20900, Italy

  • Research Site

    Naples, 80123, Italy

  • Research Site

    Padova, 35128, Italy

  • Research Site

    Pavia, 27100, Italy

  • Research Site

    Roma, 00161, Italy

  • Research Site

    Roma, 00165, Italy

  • Research Site

    Torino, 10126, Italy

  • Research Site

    Guadalajara, Jalisco, 44340, Mexico

  • Research Site

    Mexico City, Mexico City, 01120, Mexico

  • Research Site

    Monterrey, Nuevo León, 64460, Mexico

  • Research Site

    Rotterdam, 3015 CN, Netherlands

  • Research Site

    Utrecht, 3584 CS, Netherlands

  • Research Site

    Oslo, 0372, Norway

  • Research Site

    Bydgoszcz, 85-094, Poland

  • Research Site

    Krakow, 30-663, Poland

  • Research Site

    Lublin, 20-093, Poland

  • Research Site

    Wroclaw, 50-556, Poland

  • Research Site

    Zabrze, 41-800, Poland

  • Research Site

    Lisbon, 1099-023, Portugal

  • Research Site

    Porto, 4200-072, Portugal

  • Research Site

    Bucharest, 022328, Romania

  • Research Site

    Cluj-Napoca, 400177, Romania

  • Research Site

    Moscow, 115478, Russia

  • Research Site

    Saint Petersburg, 197022, Russia

  • Research Site

    Málaga, Andalusia, 29011, Spain

  • Research Site

    Seville, Andalusia, 41013, Spain

  • Research Site

    Santander, Cantabria, 39008, Spain

  • Research Site

    Barcelona, Catalonia, 08035, Spain

  • Research Site

    Barcelona, Catalonia, 08041, Spain

  • Research Site

    Santiago de Compostela, Galicia, 15706, Spain

  • Research Site

    Boadilla del Monte, Madrid, 28660, Spain

  • Research Site

    El Palmar, Murcia, 30120, Spain

  • Research Site

    Valencia, Valencia, 46026, Spain

  • Research Site

    Madrid, 28009, Spain

  • Research Site

    Madrid, 28046, Spain

  • Research Site

    Stockholm, 171 76, Sweden

  • Research Site

    Basel, 4056, Switzerland

  • Research Site

    Zurich, 8032, Switzerland

  • Research Site

    Adana, 01130, Turkey (Türkiye)

  • Research Site

    Antalya, 07059, Turkey (Türkiye)

  • Research Site

    Izmir, 35040, Turkey (Türkiye)

  • Research Site

    Kayseri, 38039, Turkey (Türkiye)

  • Research Site

    Birmingham, B4 6NH, United Kingdom

  • Research Site

    Bristol, BS2 8BJ, United Kingdom

  • Research Site

    Glasgow, G51 4TF, United Kingdom

  • Research Site

    London, WC1N 3JH, United Kingdom

  • Research Site

    Manchester, M13 9WL, United Kingdom

  • Research Site

    Newcastle upon Tyne, NE1 4LP, United Kingdom

  • Research Site

    Sheffield, S10 2TH, United Kingdom

  • Research Site

    Sutton, SM2 5PT, United Kingdom